Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults,18 through 50 years of age, who were or might be routinely exposed to N. meningitidis cultures~Exclusion Criteria:~* Previous ascertained or suspected disease caused by N. meningitidis;~* Pregnancy or breastfeeding;~* History of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;~* Any present or suspected serious acute or chronic disease~* Known or suspected autoimmune disease or impairment /alteration of immune function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 4CMenB (Type: EXPERIMENTAL): None
- MenACWY CRM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).